Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK

This article was originally published in Scrip

Executive Summary

The increasing urgency for GlaxoSmithKline PLC to build up its overall respiratory portfolio was underscored when Mylan NV confirmed it has submitted an abbreviated new drug application (ANDA) to the FDA for launch of the first generic alternative to GSK's top-selling Seretide Evohaler (salmeterol xinafoate + fluticasone propionate), known in the US as Advair Diskus.

You may also be interested in...



The Rise Of The Alt-Deal

As the pharmaceutical industry works to manage big data, improve the way drugs are used and delivered, and expand services to patients, industry is working increasingly with non-traditional partners.

Cipla-NiPPharma In Respiratory Device Deal?

Cipla Ltd. is speculated to have struck a deal with Japan's NiPPharma Co., Ltd for a device apparently meant for the Indian firm's generic Advair dry powder inhaler (DPI) but some analysts suggest that limited visibility around the trials of the firm's salmeterol + fluticasone combination in the US stay a concern for now.

Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?

Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.

Related Content

Topics

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel